| Engaging a community to focus on upper limb function in people with multiple sclerosis: the ThinkHand campaign case study A Thomson, R Horne, C Chapman, T Bharadia, P Burke, E Colwell, ... Research Involvement and Engagement 10 (1), 62, 2024 | | 2024 |
| No association between oral contraceptive exposure and subsequent MS: A population-based nested case–control study in primary care Q Zhang, AJ Noyce, J Robson, G Giovannoni, CR Marshall, R Dobson Multiple Sclerosis Journal, 13524585241258691, 2024 | | 2024 |
| Reconciling Lesions, Relapses And Smouldering Associated Worsening: A Unifying Model For Multiple Sclerosis Pathogenesis N Mistry, J Hobart, D Rog, N Muhlert, J Mathews, D Baker, G Giovannoni Multiple Sclerosis and Related Disorders, 105706, 2024 | | 2024 |
| Open access publishing and the future of scientific communication CH Hawkes, G Giovannoni, J Lechner-Scott, M Levy, A Yeh Multiple sclerosis and related disorders 86, 2024 | | 2024 |
| Targeting Epstein–Barr virus in multiple sclerosis: when and how? G Giovannoni Current Opinion in Neurology 37 (3), 228-236, 2024 | 1 | 2024 |
| Can placebo-controlled phase 2 disease-modifying therapy trials in MS still be justified? G Giovannoni, CH Hawkes, J Lechner-Scott, M Levy, EA Yeh, G Pepper, ... Multiple sclerosis and related disorders 87, 105698, 2024 | | 2024 |
| Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals A Shephard, L Kolaczkowski, N Barker, D Nahal, C Oreja-Guevara, ... Neurology and Therapy, 1-24, 2024 | | 2024 |
| Multiple sclerosis and demyelinating diseases S Leary, W Brownlee, N Barker, D Chard, J Chataway, K Chung, ... Neurology: a Queen square textbook, 603-654, 2024 | 11 | 2024 |
| Where does multiple sclerosis come from? VE Maltby, RJ Scott, G Giovannoni, CH Hawkes, M Levy, EA Yeh, ... Multiple Sclerosis and Related Disorders 85, 2024 | | 2024 |
| Under & over: a randomised controlled study to develop an upper limb rehabilitation tool for people with multiple sclerosis A Thomson, A Stennett, C Metin, J Bestwick, G Giovannoni, R Dobson Multiple Sclerosis and Related Disorders 85, 105529, 2024 | 1 | 2024 |
| Prospective Longitudinal Study of Cladribine Tablets (CLADB Study) Demonstrates Sustained Reduction in Kappa Free Light Chains in Relapsing Multiple Sclerosis (RRMS) at 96 … F Ammoscato, J Skonieczna, J Bestwick, D Holden, M Aboulwafa, ... Neurology 102 (17_supplement_1), 3589, 2024 | | 2024 |
| The Safety Profile of Fenebrutinib in Patients with Multiple Sclerosis Is Consistent with Those in Previously Studied Autoimmune Indications (P9-6.012) J Oh, A Raievska, M Sierzega, J Cerqueira, CS Riley, M Caunt, ... Neurology 102 (17_supplement_1), 3660, 2024 | | 2024 |
| Safety and Efficacy of Frexalimab in Relapsing Multiple Sclerosis: 48-week Results from the Phase 2 Open-label Extension (S31. 007) G Giovannoni, C Granziera, Y Mao-Draayer, G Cutter, O Kalbus, I Staikov, ... Neurology 102 (17_supplement_1), 3284, 2024 | | 2024 |
| 10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-term Efficacy and Safety Clinical Trial Data (S31. 005) S Hauser, L Kappos, M Filippi, J Wolinsky, M Weber, J Nicholas, ... Neurology 102 (17_supplement_1), 5124, 2024 | | 2024 |
| OCT-Angiography in AQP4-positive NMOSD: finding subclinical disease using a new tool EA Yeh, G Giovannoni, C Hawkes, RC Sergott, M Levy, J Lechner-Scott Multiple sclerosis and related disorders 84, 2024 | | 2024 |
| Impact pour le patient de 10 ans de traitement par ocrelizumab dans la sclérose en plaques: données à long terme des études de phase III OPERA et ORATORIO HM Schneble, MS Weber, L Kappos, SL Hauser, JA Nicholas, ... Revue Neurologique 180, S139, 2024 | | 2024 |
| Résultats de l’étude d’extension NOVA évaluant la préférence des patients pour l’administration sous-cutanée (SC) versus intraveineuse (IV) de natalizumab (NTZ) avec le schéma … H Wiendl, J Foley, G Defer, LZ Ryerson, JA Cohen, D Arnold, ... Revue Neurologique 180, S145, 2024 | | 2024 |
| Plasma proteomic profiles of UK Biobank participants with multiple sclerosis BM Jacobs, N Vickaryous, G Giovannoni, P Proitsi, S Waters, R Dobson Annals of Clinical and Translational Neurology 11 (3), 698-709, 2024 | | 2024 |
| Inhibition of CD40L with frexalimab in multiple sclerosis P Vermersch, C Granziera, Y Mao-Draayer, G Cutter, O Kalbus, I Staikov, ... New England Journal of Medicine 390 (7), 589-600, 2024 | 6 | 2024 |
| Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis … G Brittain, J Petrie, KEM Duffy, R Glover, K Hullock, D Papaioannou, ... BMJ open 14 (2), e083582, 2024 | 1 | 2024 |
Ludwig KapposUniversity Hospital Basel在 uhbs.ch 的电子邮件经过验证
